Prof. Dingwei Ye,  Director of the Multi-disciplinary Team for GU cancer, Director of Fudan University Prostate Cancer Institute, President of genitourinary cancer committee of Chinese Anti-Cancer Association, Standing Committee member of Chinese Society of Clinical Oncology(CSCO)，Vice chairs of RCC committee and Immunotherapy committee of  CSCO, Vice chair of Chinese Anti-Cancer Association Family Hereditary Oncology group, deputy leader of writing group of NCCN Guidelines for diagnosis and treatment of renal cancer (Chinese edition)，committee member of NCCN Asia consensus of prostate cancer and bladder cancer, Vice chair of Shanghai Medical Doctor Association urology branch decisive reviewer of National Scientific Foundation of China, executive member of Asian Pacific Prostate Society, Vice President of Asia Cry-surgery Society.  

Prof. Ye Presided over more than 50 national, provincial and ministerial scientific research funds. Prof. Ye had 543 papers published in peer review journals as the first author or corresponding author (296 SCI), edited 9 monographs, obtained 19 patents. He has led over 50 international or national multicenter clinical trials and studies for GU cancer as leading PI. As the first accomplisher, Prof. Ye won the first prize of Shanghai Science and Technology Progress, First Prize of Science and Technology Achievement of Ministry of Education, Shanghai Medical Science and Technology Award first prize, Second prize of Chinese Medicine Award. As the third accomplisher, Prof. Ye won First Prize of National Science and Technology Progress in 2012. Prof. Ye awarded as Young and middle-aged experts with outstanding contributions by the National Health and Family Planning Commission, Wu Jieping Urology Award, Shanghai Leading Talents, Shanghai medical leading talents, Excellent Academic Leader of Shanghai, Advanced Worker in National Health and Family Planning Commission, and enjoyed special government allowance of The State Council.